Clinical Trials Logo

Filter by:
NCT ID: NCT06269510 Not yet recruiting - Liver Diseases Clinical Trials

Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients

Start date: April 2025
Phase: N/A
Study type: Interventional

The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.

NCT ID: NCT06269055 Not yet recruiting - Clinical trials for Gadolinium Deposition Disease

Long-term Result of DTPA (Diethylenetriamine Pentaacetate) Chelation for Gadolinium Deposition Disease

Start date: May 15, 2024
Phase:
Study type: Observational

This study is aimed at describing the degree of benefit, if any, and the adverse effects, if any, from receiving 5 or more treatment sessions of Gadolinium Deposition Disease using two-day chelation treatment with the chelating agents Calcium Diethylenetriamine pentaacetate (Ca-DTPA) and Zinc Diethylenetriamine pentaacetate (Zn-DTPA).

NCT ID: NCT06268665 Not yet recruiting - Breast Cancer Clinical Trials

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

Start date: February 28, 2024
Phase: Phase 2
Study type: Interventional

This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy. Eligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).

NCT ID: NCT06268015 Not yet recruiting - Colorectal Cancer Clinical Trials

Botensilimab and Balstilimab Optimization in Colorectal Cancer

BBOpCo
Start date: July 2024
Phase: Phase 2
Study type: Interventional

This is a single-arm, interventional, pilot clinical trial. Fifteen evaluable patients will have tumor-informed ctDNA testing at baseline and start botensilimab and balstilimab treatment. They will receive botensilimab and balstilimab in 6-week cycles until progression, after which mFOLFOX6 and bevacizumab or panitumumab will be added to the regimen. Subjects will have safety testing at baseline and every two weeks while on study drug. Study treatment with botensilimab and balstilimab, mFOLFOX6, and bevacizumab or panitumumab will be continued until radiographic or clinical progression, toxicity, or patient withdrawal. Subjects will have one safety follow up visit 30 days after the last treatment and will be followed for survival every 12 weeks for up to 2 years.

NCT ID: NCT06267872 Not yet recruiting - HIV Clinical Trials

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

Start date: June 14, 2024
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, phase 1 clinical trial to test two human immunodeficiency virus (HIV) vaccines with two adjuvants. An adjuvant is an ingredient used with some vaccines that may help people make an immune response. HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). About 42 people will take part in the HVTN 309 clinical trial. This clinical trial will take place at multiple sites in the US and South Africa and the clinical trial is divided into 3 parts: Part A, Part B and Part C. About 3 people will participate in Part A of this study. After results from Part A are reviewed, it will be determined whether or not Part B and Part C of the clinical trial will proceed.

NCT ID: NCT06267339 Not yet recruiting - Children Clinical Trials

Effects of Transcranial Random Noise Stimulation on Motor Learning in Typically Developing Adolescents

Start date: September 1, 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this study is to compare motor learning rates on two different tasks, when combined with non-invasive brain stimulation.

NCT ID: NCT06267274 Not yet recruiting - Ocular Hypertension Clinical Trials

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

NCT ID: NCT06266702 Not yet recruiting - Nutrition, Healthy Clinical Trials

Evaluation of a Nutritional Technology for Vitamin D Absorption

Start date: March 2024
Phase: N/A
Study type: Interventional

This is a prospective, 2-group crossover, randomized, double-blind study to evaluate nutrient absorption.

NCT ID: NCT06266611 Not yet recruiting - Depression Clinical Trials

Cannabis for Palliative Care in Cancer

ARCTiC
Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) versus placebo on measures of sleep, pain, mood, subjective and objective cognitive functioning, and quality of life within 185 cancer patients.

NCT ID: NCT06266416 Not yet recruiting - HIV Infections Clinical Trials

IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)

IMAGE
Start date: April 25, 2024
Phase: N/A
Study type: Interventional

The scientific premise of this research is that individual, interpersonal, and structural factors impact Black girls' sexual reproductive health outcomes (sexually transmitted infection (STI) and Human Immunodeficiency Virus (HIV)) and experience of sexual violence. This study expands STI/HIV prevention programs to include Black male caregivers, a potentially valuable yet underutilized resource to protect Black girls and reduce their exposure to STI/HIV and sexual violence.